RaySearch Laboratories AB Class B ( (RSLBF) ) has released its Q2 earnings. Here is a breakdown of the information RaySearch Laboratories AB Class B presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RaySearch Laboratories AB is a medical technology company specializing in software solutions to enhance cancer treatment, operating within the healthcare industry. In the second quarter of 2025, RaySearch Laboratories reported a decline in net sales by 4.4% compared to the previous year, with a notable decrease in license revenue and an increase in support revenue. The company also launched new versions of its RayStation and RayCare systems, highlighting advancements in treatment planning and clinical workflow management. Despite the decline in quarterly sales, the company experienced a strong order intake for the first half of 2025, indicating robust demand for its products. Looking ahead, RaySearch remains optimistic about its growth prospects, maintaining its operating margin target and focusing on strategic partnerships to drive future success.